Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

Efficacy and Safety of Triple Therapy Based on Prognostic Risk Stratification in Patients With Anti-MDA5 Antibody-positive Dermatomyositis: a Multicenter, Prospective, Randomized Controlled Study

We conduct this study to investigate the efficacy of triple therapy (high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor) compared with dual-therapy regimens (high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor) and whether it reduces the risk of poor pulmonary prognosis in patients with moderate to high risk anti-MDA5+ DM.

Inclusion Criteria:

• Adult patients meet the diagnostic criteria for dermatomyositis of Bohan and Peter
• Anti-MDA5 Antibody-positive

Exclusion Criteria:

• Complicated with other connective tissue diseases
• Complicated with cardiovascular and respiratory disease caused by other reasons
• Interstitial lung disease caused by environment and drugs
• Patients with key research missing data or without informed consent